Friday, June 11, 2021 12:24 AM
RANCHO CORDOVA, Calif.—Eighty percent of Americans say pandemic-prompted screen time put their eyes in "overdrive," according to the results of a new survey commissioned by VSP Vision Care
Thursday, June 10, 2021 12:24 AM
SEATTLE and BOSTON—Greg Kunst has been named chief executive officer of newly launched Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases.
Wednesday, June 9, 2021 12:15 AM
TOKYO—An international team of researchers has taken an important step toward understanding a powerful potential treatment for myopia, which is fast becoming a public health crisis in Asia.
Friday, June 4, 2021 12:27 AM
BRIDGEWATER, N.J. and ALPHARETTA, Ga.—Bausch + Lomb
and Clearside Biomedical
announced that the U.S. Food and Drug Administration
(FDA) has accepted the resubmitted New Drug Application for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension). FDA determined that the filing is a Class 2 resubmission and therefore assigned a Prescription Drug User Fee Act (PDUFA) action date of October 30, 2021. XIPERE is an investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.
Friday, June 4, 2021 12:18 AM
LONDON—The Wellcome Trust
and the Chen Yet-Sen Family Foundation
announced a £3.5 million contribution to support the launch of a five-year research project that will explore vision care as a driver of development across the life course. The project, known as ENGINE, comprises a four-country suite of trials examining the impact of glasses on promoting better living from childhood through to old age, the two organizations said in a statement. ENGINE examines how eyeglasses, an affordable, effective and widely- available treatment, can help achieve the United Nation’s Sustainable Development Goals across the life course in the following ways:
Wednesday, June 2, 2021 12:24 AM
BRIDGEWATER, N.J., and CHICAGO—Bausch + Lomb
, a leading global eye health business, and Prevent Blindness
, the nation’s oldest volunteer eye health non-profit organization, announced that they are joining forces during Cataract Awareness Month in June to educate the public and raise awareness of the symptoms, causes and treatment options for cataracts, the leading cause of vision loss in the U.S. and the leading cause of blindness worldwide. Treatment options include cataract surgery, which is one of the most effective and common medical procedures with an overall success rate of 99 percent when performed in appropriate settings.
Wednesday, June 2, 2021 12:18 AM
SAN RAMON, Calif.—A new paper that has been accepted for publication in Ophthalmic & Physiological Optics
, the peer-reviewed journal of The College of Optometrists
(UK), furthers understanding of myopia control efficacy in the context of normal childhood eye growth. The paper, “Axial Length Targets for Myopia Control,” is now available online via Open Access
. Since young eyes grow, even when not myopic, the paper compares axial elongation among children who remain emmetropic, children with untreated myopia progression, and children with myopia managed with CooperVision MiSight 1 day myopia control contact lenses.
Thursday, May 27, 2021 12:15 AM
SAN RAMON, Calif.—To advance the education of future eyecare professionals in myopia management and specialty contact lenses, CooperVision
and CooperVision Specialty EyeCare recently sponsored the fourth annual Contact Lens and Pediatric Residency Summit.
Monday, May 24, 2021 12:24 AM
CHICAGO—In a recent study published in JAMA Ophthalmology
, “Prevalence of Visual Acuity Loss or Blindness in the US
,” researchers estimate permanent vision loss and blindness in Americans of all ages, including people younger than 40 years old, and adults in group quarters, such as nursing homes or jails.
Monday, May 24, 2021 12:15 AM
, the developer of wearable AI-powered vision diagnostics and augmentation software, closed its Series A financing of $30 million to advance the company’s eye diagnostic and vision correction technology platform. An estimated 450 million people worldwide experience visual field defects or double vision, according to Heru, but limited access can mean long waits for eye appointments. Heru’s patented autonomous AI-powered vision diagnostics and augmentation software, designed for use on commercially available AR/VR devices, helps ensure that patients’ vision can be tested earlier so that diagnosed defects can be treated in a timely manner, the company said.
Tuesday, May 18, 2021 12:30 AM
yesterday announced that the U.S. Food and Drug Administration
(FDA) has granted “Breakthrough Device” designation to its Essilor Stellest spectacle lens, the company’s new generation lens developed to correct myopia and slow down the progression of myopia in children. The designation of the Essilor’s Stellest spectacle lens as a “Breakthrough Device” by the FDA, that will lead to further U.S. research and FDA review, builds on the publication of groundbreaking two-year results of an ongoing three-year clinical trial, in China, in myopic children.
Tuesday, May 18, 2021 12:21 AM
NEW DELHI & MUMBAI, India—Lenskart
, a top India-based omni-channel eyewear retailer and global investment firm KKR
announced the signing of definitive agreements under which KKR will invest $95 million in Lenskart via a secondary stake acquisition.
Tuesday, May 18, 2021 12:15 AM
LOS ANGELES, Calif.—Second Sight Medical Products
, a leading developer of implantable visual prosthetics, announced that it has received notice from the National Institutes of Health
(NIH) of the release of year three funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the Orion Trial), grant UH3NS103442. The NIH released $1.4 million of the $6.4 million planned five-year grant. Second Sight uses the funds primarily to pay UCLA
and Baylor College of Medicine
to conduct the Orion Trial.
Thursday, May 13, 2021 12:24 AM
JACKSONVILLE, Fla.—Johnson & Johnson Vision
said Wednesday that the Food and Drug Administration (FDA) has approved Acuvue Abiliti Overnight Therapeutic Lenses
. This new lens is the first and only FDA approved orthokeratology (ortho-k) contact lens for the management of myopia, according to the announcement. The lens, expected to launch by the end of 2021, will be available in sphere and toric designs to correct various combinations of corneal shapes and refractive errors. ECPs and parents who want more information can visit the site here